We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+16.37%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$441M
AUM Growth
+$26.2M
Cap. Flow
+$45.7M
Cap. Flow %
10.38%
Top 10 Hldgs %
36.84%
Holding
138
New
52
Increased
12
Reduced
20
Closed
21

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$10.8M
2
INSM icon
Insmed
INSM
+$9.42M
3
BBIO icon
BridgeBio Pharma
BBIO
+$6.93M
4
APLS
Apellis Pharmaceuticals
APLS
+$5.77M
5
BCYC
Bicycle Therapeutics
BCYC
+$5.19M

Top Sells

Rank Stock Value
1
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$18.8M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$10.2M
3
CLDX icon
Celldex Therapeutics
CLDX
+$6.97M
4
BHVN icon
Biohaven
BHVN
+$6.93M
5
ETNB
89bio
ETNB
+$5.78M

Sector Composition

Rank Sector Weight
1 Healthcare 53.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHVN icon
26
Biohaven
BHVN
$2.08B
$5.5M 1.25%
402,326
-435,174
-52% -$6.93M
TCON
27
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$5.23M 1.19%
138,277
– –
ISEE
28
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$5.19M 1.18%
213,521
-163,500
-43% -$3.58M
PTGX icon
29
CALL
Protagonist Therapeutics
PTGX
$8.92B
$4.86M 1.1%
+211,400
New +$3.55M
PTGX icon
30
PUT
Protagonist Therapeutics
PTGX
$8.92B
$4.86M 1.1%
+211,400
New +$3.55M
BMRN icon
31
BioMarin Pharmaceuticals
BMRN
$11.7B
$4.86M 1.1%
+50,000
New +$5.18M
ACRS icon
32
CALL
Aclaris Therapeutics
ACRS
$743M
$4.77M 1.08%
+589,300
New +$7.48M
VRNA
33
DELISTED
Verona Pharma
VRNA
$4.59M 1.04%
228,677
-26,454
-10% -$571K
ALT icon
34
PUT
Altimmune
ALT
$580M
$4.55M 1.03%
+1,077,200
New +$12.8M
BCYC
35
Bicycle Therapeutics
BCYC
$280M
$4.41M 1%
+207,112
New +$5.19M
AMLX icon
36
CALL
Amylyx Pharmaceuticals
AMLX
$2.31B
$4.4M 1%
+150,000
New +$5.21M
BCYC
37
CALL
Bicycle Therapeutics
BCYC
$280M
$4.25M 0.97%
+200,000
New +$5.02M
ROIV icon
38
Roivant Sciences
ROIV
$24.9B
$4.24M 0.96%
+575,000
New +$4.73M
RCUS icon
39
Arcus Biosciences
RCUS
$3.55B
$4.2M 0.95%
230,000
+92,013
+67% +$1.76M
CLDX icon
40
PUT
Celldex Therapeutics
CLDX
$3.02B
$3.96M 0.9%
+110,000
New +$4.75M
JBIO
41
Jade Biosciences
JBIO
$1.22B
$3.94M 0.89%
5,576
+1,921
+53% +$1.59M
MRUS
42
DELISTED
Merus
MRUS
$3.84M 0.87%
208,650
+52,650
+34% +$917K
CLDX icon
43
Celldex Therapeutics
CLDX
$3.02B
$3.82M 0.87%
106,057
-161,419
-60% -$6.97M
ALT icon
44
CALL
Altimmune
ALT
$580M
$3.79M 0.86%
898,600
+321,200
+56% +$3.82M
XLV icon
45
State Street Health Care Select Sector SPDR ETF
XLV
$42.2B
$3.56M 0.81%
+27,469
New +$3.59M
INSM icon
46
CALL
Insmed
INSM
$22B
$3.41M 0.77%
+200,000
New +$3.89M
ALT icon
47
Altimmune
ALT
$580M
$2.86M 0.65%
677,300
+403,868
+148% +$4.8M
BIVI icon
48
BioVie
BIVI
$10.8M
$2.82M 0.64%
+3,486
New +$2.31M
ARDX icon
49
Ardelyx
ARDX
$1.25B
$2.77M 0.63%
578,825
-800,000
-58% -$2.7M
DCPH
50
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$2.7M 0.61%
174,510
-192,609
-52% -$3.22M
1
2
3 4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q1 2023 Portfolio in Review

As of Q1 2023, Ikarian Capital held 138 positions worth $441M, up 6.3% from $415M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Ikarian Capital deployed $45.7M of net new capital in Q1 2023, opening 52 new positions and adding to 12 existing holdings. Its largest new stake was Merck: 100,000 shares worth $10.6M.

By sector, the portfolio is most concentrated in Healthcare at 53% of assets, down from 58% a quarter earlier.

On the sell side, the largest reduction was Prometheus Biosciences, Inc. Common Stock, an estimated $18.8M trimmed.

  • Ikarian Capital's largest Q1 2023 buy was Merck: 100,000 shares worth $10.6M.
  • Ikarian Capital added most to Altimmune in Q1 2023, an estimated $4.8M increase.
  • Ikarian Capital's biggest Q1 2023 reduction was Prometheus Biosciences, Inc. Common Stock, cutting an estimated $18.8M.
  • Ikarian Capital fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023, selling an estimated $10.2M.
  • Ikarian Capital's ten largest holdings make up 37% of its $441M portfolio in Q1 2023.
  • Ikarian Capital opened 52 new positions and closed 21 in Q1 2023.
  • Ikarian Capital's portfolio value rose 6.3% quarter-over-quarter to $441M.

Based on Ikarian Capital's 13F filing for Q1 2023, filed 15 May 2023.